keyword
MENU ▼
Read by QxMD icon Read
search

Memory t cell cancer

keyword
https://www.readbyqxmd.com/read/29159802/adenovirus-vector-based-prime-boost-vaccination-via-heterologous-routes-induces-cervicovaginal-cd8-t-cell-responses-against-hpv16-oncoproteins
#1
Nicolas Çuburu, Selina Khan, Cynthia D Thompson, Rina Kim, Jort Vellinga, Roland Zahn, Douglas R Lowy, Gert Scheper, John T Schiller
Recent advances in immunotherapy against cancer underscore the importance of T lymphocytes and tumor microenvironment, but few vaccines targeting cancer have been approved likely due in part to the dearth of common tumor antigens, insufficient immunogenicity and the evolution of immune evasion mechanisms during the progression to malignancy. Human papillomaviruses (HPV) are the primary etiologic agents of cervical cancer and progression from persistent HPV-infection to cervical intraepithelial lesions and eventually cancer requires persistent expression of the oncoproteins E6 and E7...
November 21, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29157306/a-pilot-study-of-the-immunogenicity-of-a-9-peptide-breast-cancer-vaccine-plus-poly-iclc-in-early-stage-breast-cancer
#2
Patrick M Dillon, Gina R Petroni, Mark E Smolkin, David R Brenin, Kimberly A Chianese-Bullock, Kelly T Smith, Walter C Olson, Ibrahim S Fanous, Carmel J Nail, Christiana M Brenin, Emily H Hall, Craig L Slingluff
BACKGROUND: Breast cancer remains a leading cause of cancer death worldwide. There is evidence that immunotherapy may play a role in the eradication of residual disease. Peptide vaccines for immunotherapy are capable of durable immune memory, but vaccines alone have shown sparse clinical activity against breast cancer to date. Toll-like receptor (TLR) agonists and helper peptides are excellent adjuvants for vaccine immunotherapy and they are examined in this human clinical trial. METHODS: A vaccine consisting of 9 MHC class I-restricted breast cancer-associated peptides (from MAGE-A1, -A3, and -A10, CEA, NY-ESO-1, and HER2 proteins) was combined with a TLR3 agonist, poly-ICLC, along with a helper peptide derived from tetanus toxoid...
November 21, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29150554/cancer-cells-induce-interleukin-22-production-from-memory-cd4-t-cells-via-interleukin-1-to-promote-tumor-growth
#3
Cornelia Voigt, Peter May, Adrian Gottschlich, Anamarija Markota, Daniel Wenk, Inga Gerlach, Sebastian Voigt, Georgios T Stathopoulos, Kristina A M Arendt, Constanze Heise, Felicitas Rataj, Klaus-Peter Janssen, Melanie Königshoff, Hauke Winter, Isabelle Himsl, Wolfgang E Thasler, Max Schnurr, Simon Rothenfußer, Stefan Endres, Sebastian Kobold
IL-22 has been identified as a cancer-promoting cytokine that is secreted by infiltrating immune cells in several cancer models. We hypothesized that IL-22 regulation would occur at the interface between cancer cells and immune cells. Breast and lung cancer cells of murine and human origin induced IL-22 production from memory CD4(+) T cells. In the present study, we found that IL-22 production in humans is dependent on activation of the NLRP3 inflammasome with the subsequent release of IL-1β from both myeloid and T cells...
November 17, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29147626/functional-t-cells-targeting-tumor-associated-antigens-are-predictive-for-recurrence-free-survival-of-patients-with-radically-operated-non-small-cell-lung-cancer
#4
Seyer Safi, Yoshikane Yamauchi, Anchana Rathinasamy, Slava Stamova, Martin Eichhorn, Arne Warth, Geraldine Rauch, Hendrik Dienemann, Hans Hoffmann, Philipp Beckhove
In this prospective study, we examined postoperative follow-up and preoperative IFN-γ T cell responses against 14 non-small cell lung cancer (NSCLC)-associated antigens in the blood of 51 patients with NSCLC, 7 patients with benign pulmonary tumors, and 10 tumor-free patients by enzyme-linked immunospot assay. The phenotype and function of T cells specific for tumor-associated antigens (TAAs) in the blood or tumor tissue of 9 NSCLC patients were characterized in detail using TNF-α, IL-2, and IFN-γ cytokine capture assays...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29147623/tissue-resident-memory-t-cells-play-a-key-role-in-the-efficacy-of-cancer-vaccines
#5
C Granier, C Blanc, S Karaki, T Tran, H Roussel, E Tartour
Resident memory CD8(+)T cells (TRM) usually defined by the CD103 marker represent a new subset of long-lived memory T cells that remain in the tissues. We directly demonstrate their specific role in cancer vaccine-induced tumor regression. In human, they also seem to play a major role in tumor immunosurveillance.
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29147022/conventional-cd4-t-cells-present-bacterial-antigens-to-induce-cytotoxic-and-memory-cd8-t-cell-responses
#6
Aránzazu Cruz-Adalia, Guillermo Ramirez-Santiago, Jesús Osuna-Pérez, Mónica Torres-Torresano, Virgina Zorita, Ana Martínez-Riaño, Viola Boccasavia, Aldo Borroto, Gloria Martínez Del Hoyo, José María Gozález-Granado, Balbino Alarcón, Francisco Sánchez-Madrid, Esteban Veiga
Bacterial phagocytosis and antigen cross-presentation to activate CD8(+) T cells are principal functions of professional antigen presenting cells. However, conventional CD4(+) T cells also capture and kill bacteria from infected dendritic cells in a process termed transphagocytosis (also known as transinfection). Here, we show that transphagocytic T cells present bacterial antigens to naive CD8(+) T cells, which proliferate and become cytotoxic in response. CD4(+) T-cell-mediated antigen presentation also occurs in vivo in the course of infection, and induces the generation of central memory CD8(+) T cells with low PD-1 expression...
November 17, 2017: Nature Communications
https://www.readbyqxmd.com/read/29138841/enhanced-activated-t%C3%A2-cell-subsets-in-prostate-cancer-patients-receiving-iodine-125-low-dose-rate-prostate-brachytherapy
#7
Makoto Kubo, Takefumi Satoh, Hiromichi Ishiyama, Ken-Ichi Tabata, Hideyasu Tsumura, Shoko Komori, Masatsugu Iwamura, Shiro Baba, Kazushige Hayakawa, Toshihiko Kawamura, Fumiya Obata
Radiotherapy (RT) is one of the most important treatments for prostate cancer. Although RT can kill cancer cells through direct and indirect effects of radiation, it occasionally induces an abscopal effect whereby localized radiation treatment is associated with elimination of metastatic cancer at a distance from the irradiated area. Thus, RT may induce an effective antitumor immune response, although the mechanism involved has remained unclear. The present was designed to evaluate this effect of RT in 36 patients with prostate cancer who provided informed consent prior to enrollment in this clinical trial...
November 13, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29138340/phase-i-study-of-chimeric-antigen-receptor-modified-t-cells-in-patients-with-egfr-positive-advanced-biliary-tract-cancers
#8
Yelei Guo, Kai-Chao Feng, Yang Liu, Zhiqiang Wu, Hanren Dai, Qing-Ming Yang, Yao Wang, Hejin Jia, Weidong Han
PURPOSE: This study is an expanded and parallel clinical trial of epidermal growth factor receptor (EGFR)-specific chimeric antigen receptor-engineered autologous T (CART) cell immunotherapy (NCT01869166) to assess the safety and activity of CART-EGFR cell therapy in EGFR-positive advanced unresectable, relapsed/metastatic biliary tract cancers (BTCs). PATIENTS AND METHODS: Patients with EGFR-positive (>50%) advanced unresectable, relapsed/metastatic BTCs were enrolled...
November 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29137877/immune-analysis-of-radium-223-in-patients-with-metastatic-prostate-cancer
#9
Joseph W Kim, Min Sun Shin, Youna Kang, Insoo Kang, Daniel P Petrylak
BACKGROUND: Radium223 (Ra223) delivers high-energy radiation to osteoblastic metastasis of prostate cancer, resulting in irreparable double-stranded DNA damage. The effects of Ra223 on CD8+ T cell subsets in patients with prostate cancer is unknown. PATIENTS AND METHODS: Fifteen men with metastatic prostate cancer with clinical indication for Ra223 without any autoimmune or immune deficiency conditions were enrolled. Patients received a course of Ra223 50 kBq/kg...
October 24, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29137371/peripheral-cd4-na%C3%A3-ve-memory-ratio-is-an-independent-predictor-of-survival-in-non-small-cell-lung-cancer
#10
Peng Yang, Junhong Ma, Xin Yang, Wei Li
Background: To investigate the clinical significance of naïve T cells, memory T cells, CD45RA+CD45RO+ T cells, and naïve/memory ratio in non-small cell lung cancer (NSCLC) patients. Methods: Pretreatment peripheral blood samples from 76 NSCLC patients and 28 age- and sex-matched healthy volunteers were collected and tested for immune cells by flow cytometry. We compared the expression of these immune cells between patients and healthy controls and evaluated their predictive roles for survival in NSCLC by cox proportional hazards model...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29133898/intertwining-dna-rna-nanocapsules-loaded-with-tumor-neoantigens-as-synergistic-nanovaccines-for-cancer-immunotherapy
#11
Guizhi Zhu, Lei Mei, Harshad D Vishwasrao, Orit Jacobson, Zhantong Wang, Yijing Liu, Bryant C Yung, Xiao Fu, Albert Jin, Gang Niu, Qin Wang, Fuwu Zhang, Hari Shroff, Xiaoyuan Chen
Nanomedicines that co-deliver DNA, RNA, and peptide therapeutics are highly desirable yet remain underdeveloped for cancer theranostics. Herein, we report self-assembled intertwining DNA-RNA nanocapsules (iDR-NCs) that efficiently delivered synergistic DNA CpG and short hairpin RNA (shRNA) adjuvants, as well as tumor-specific peptide neoantigens into antigen presenting cells (APCs) in lymph nodes for cancer immunotherapy. These nanovaccines were prepared by (1) producing tandem CpG and shRNA via concurrent rolling circle replication and rolling circle transcription, (2) self-assembling CpG and shRNA into DNA-RNA microflowers, (3) shrinking microflowers into iDR-NCs using PEG-grafted cationic polypeptides, and (4) physically loading neoantigen into iDR-NCs...
November 14, 2017: Nature Communications
https://www.readbyqxmd.com/read/29124456/serial-immunological-parameters-in-a-phase-ii-trial-of-exemestane-and-low-dose-oral-cyclophosphamide-in-advanced-hormone-receptor-positive-breast-cancer
#12
Maryann Kwa, Xiaochun Li, Yelena Novik, Ruth Oratz, Komal Jhaveri, Jennifer Wu, Ping Gu, Marleen Meyers, Franco Muggia, James Speyer, Alyssa Iwano, Maryam Bonakdar, Lina Kozhaya, Ece Tavukcuoglu, Bahar Budan, Roy Raad, Judith D Goldberg, Derya Unutmaz, Sylvia Adams
BACKGROUND AND PURPOSE: Resistance to endocrine therapies in hormone receptor (HR)-positive breast cancer is a significant challenge. Prior studies have shown that low-dose oral cyclophosphamide can transiently deplete regulatory T cells (Tregs) and improve anti-tumor immunity. We investigated the combination of exemestane with cyclophosphamide in patients with advanced HR-positive breast cancer and assessed changes in circulating immune cell subsets. METHODS: This was a single-arm phase II trial of exemestane with cyclophosphamide in patients with metastatic HR-positive/HER2-negative breast cancer who had progressed on prior endocrine therapy (ClinicalTrials...
November 9, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29123962/distinctive-features-of-tumor-infiltrating-%C3%AE-%C3%AE-t-lymphocytes-in-human-colorectal-cancer
#13
S Meraviglia, E Lo Presti, M Tosolini, C La Mendola, V Orlando, M Todaro, V Catalano, G Stassi, G Cicero, S Vieni, J J Fourniè, F Dieli
γδ T cells usually infiltrate many different types of cancer, but it is unclear whether they inhibit or promote tumor progression. Moreover, properties of tumor-infiltrating γδ T cells and those in the corresponding normal tissue remain largely unknown. Here we have studied features of γδ T cells in colorectal cancer, normal colon tissue and peripheral blood, and correlated their levels with clinicopathologic hallmarks. Flow cytometry and transcriptome analyses showed that the tumor comprised a highly variable rate of TILs (5-90%) and 4% γδ T cells on average, with the majority expressing Vδ1...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29120508/synthesis-and-immunological-evaluation-of-a-multicomponent-cancer-vaccine-candidate-containing-a-long-muc1-glycopeptide
#14
Geert-Jan Boons, Nitin T Supekar, Vani Lakshminarayanan, Chantelle J Capicciotti, Anju Sirohiwal, Cathy S Madsen, Margreet A Wolfert, Peter A Cohen, Sandra J Gendler
A fully synthetic MUC1-based cancer vaccine has been designed and chemically synthesized that contains an endogenous helper T-epitope (MHC class II epitope). The vaccine elicited robust IgG titers that could neutralize cancer cells by antibody-dependent cell-mediated cytotoxicity (ADCC). It also activated cytotoxic T-lymphocytes and collectively the immunological data demonstrate engagement of helper T-cells in immune activation. A synthetic methodology was developed for a penta-glycosylated MUC1 glycopeptide and anti-sera of mice immunized by the new vaccine recognized such a structure...
November 9, 2017: Chembiochem: a European Journal of Chemical Biology
https://www.readbyqxmd.com/read/29115974/stat3-blocked-whole-cell-hepatoma-vaccine-induces-cellular-and-humoral-immune-response-against-hcc
#15
Qiuju Han, Yaqun Wang, Min Pang, Jian Zhang
BACKGROUND: Whole-cell tumor vaccines have shown much promise; however, only limited success has been achieved for the goal of eliciting robust tumor-specific T-cell responses. METHODS: Hepatocellular carcinoma (HCC) cells, H22 and Hepa1-6, were modified by blocking the STAT3 signaling pathway with a STAT3 decoy oligodeoxynucleotide, and the immunogenicity and possibility of using these cell lysates as a vaccine were evaluated. RESULTS: STAT3-blocked whole HCC cell lysates inhibited tumor growth and tumorigenesis, and prolonged the survival of tumor-bearing mice...
November 7, 2017: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/29115604/genetically-engineered-recombinant-adenovirus-expressing-interleukin%C3%A2-2-for-hepatocellular-carcinoma-therapy
#16
Yunpeng Sun, Huanhuan Wu, Gang Chen, Xiaming Huang, Yunfeng Shan, Hongqi Shi, Qiyu Zhang, Yihu Zheng
Regulatory and effector T cells possess immunological cytotoxicity for tumor cells in the tumor microenvironment during tumor progression and are the primary suppressors inhuman cancer therapy. Interleukin‑2 (IL‑2) is an anticancer cytokine, which triggers human innate and adaptive immunity by stimulating T cell propagation and lymphocyte infiltration into tumor sites. IL‑2 has been used successfully for cancer therapy. Recombinant adenovirus expressing IL‑2 (rAd‑IL‑2) injection is a gene therapy agent that may improve prognosis of hepatocellular carcinoma (HCC) patients...
October 27, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29114389/adoptive-cell-therapy-with-cd4-t-helper-1-cells-and-cd8-cytotoxic-t-cells-enhances-complete-rejection-of-an-established-tumour-leading-to-generation-of-endogenous-memory-responses-to-non-targeted-tumour-epitopes
#17
Kunyu Li, Braeden Donaldson, Vivienne Young, Vernon Ward, Christopher Jackson, Margaret Baird, Sarah Young
The results of adoptive T-cell therapies (ACTs) are very encouraging and show clinical evidence that ACT can provide a cure for patients with metastatic disease. However, various response rates and long-term cancer remission have been observed in different ACT trials. The types of T cells, prior treatment with chemotherapy and co-administration of other immune-target therapies have been found to influence the efficacy of ACT. In this study, we investigate the ability of ACT using CD4(+) T helper 1 (Th1) cells and CD8(+) cytotoxic T lymphocytes (CTLs) to reject the growth of established B16-ovalbumin (OVA) melanoma...
October 2017: Clinical & Translational Immunology
https://www.readbyqxmd.com/read/29112124/gene-regulatory-network-rewiring-in-the-immune-cells-associated-with-cancer
#18
Pengyong Han, Chandrasekhar Gopalakrishnan, Haiquan Yu, Edwin Wang
The gene regulatory networks (GRNs) of immune cells not only indicate cell identity but also reveal the dynamic changes of immune cells when comparing their GRNs. Cancer immunotherapy has advanced in the past few years. Immune-checkpoint blockades (i.e., blocking PD-1, PD-L1, or CTLA-4) have shown durable clinical effects on some patients with various advanced cancers. However, major gaps in our knowledge of immunotherapy have been recognized. To fill these gaps, we conducted a systematic analysis of the GRNs of key immune cell subsets (i...
November 7, 2017: Genes
https://www.readbyqxmd.com/read/29108268/inherent-characteristics-of-metachronous-metastatic-renal-cell-carcinoma-in-the-era-of-targeted-agents
#19
Jang Hee Han, Seung Hwan Lee, Won Sik Ham, Woong Kyu Han, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong, Young Eun Yoon
Background: To assess the prognostic and predictive factors of time to treatment failure (TTF) and overall survival (OS), respectively, in patients with metachronous metastatic renal cell carcinoma (mRCC) who were treated with targeted agents. Materials and Methods: We retrospectively reviewed metachronous mRCC patients, defined as individuals diagnosed with metastatic disease >3 months after initial nephrectomy, treated at an institute since 2005. Cox proportional hazard regression analysis was performed to discover the most determinant variables associated with TTF and OS...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29103998/tlr8-combined-withtlr3-or-tlr4-agonists-enhances-dc-nk-driven-effector-tc1-cells
#20
Mahyar Nouri-Shirazi, Saba Tamjidi, Erika Nourishirazi, Elisabeth Guinet
BACKGROUND: Most current prophylactic vaccines confer protection primarily through humoral immunity. Indeed, aluminum salts which have been widely used as adjuvants in vaccines primarily enhance Th2-driven antibody responses. Therefore, new vaccines formulation is moving toward a careful selection of adjuvants that also elicit significant Th1 or Tc1 responses. Several TLR agonists have been tested as potential new adjuvants in clinical and preclinical studies with some efficacy. These studies suggest that combining more than one of TLR ligands enhances the magnitude of immune responses to cancer and infectious disease...
November 2, 2017: Immunology Letters
keyword
keyword
109581
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"